Drug intelligence / Profile preview

LY-2624803

Development stage: Phase 2
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Oral

Overview

LY-2624803 is a small molecule drug developed by Eli Lilly for the treatment of insomnia. It acts as a modulator of both the histamine H1 receptor and the serotonin 5-HT2A receptor, exhibiting both agonist and antagonist activity at these targets. The compound belongs to the dibenzoxazepine class of organic compounds. Clinical development reached Phase 2 for sleep initiation and maintenance disorders (insomnia), but was discontinued after Phase 2 trials in the United States and Phase 1 trials in the United Kingdom[2][6]. No brand or generic names beyond its code names are reported.

Targets

HTR2A (Serotonin receptor 5-HT2A)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on LY-2624803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY-2624803.

Explore the full profile